More Frequent Hemodialysis: What Do We Know? Where Do We Stand?

2011 ◽  
pp. 10-16 ◽  
Author(s):  
Jochen G. Raimann ◽  
Stephan Thijssen ◽  
Rosio Ramos ◽  
Nathan W. Levin
Keyword(s):  
More Frequent Hemodialysis ◽  
Frequent Hemodialysis

scholarly journals Effect of More Frequent Hemodialysis on Cognitive Function in the Frequent Hemodialysis Network Trials

2013 ◽  
Vol 61 (2) ◽  
pp. 228-237 ◽  
Author(s):  
Manjula Kurella Tamura ◽  
Mark L. Unruh ◽  
Allen R. Nissenson ◽  
Brett Larive ◽  
Paul W. Eggers ◽  
...  
Keyword(s):  
Cognitive Function ◽  
More Frequent Hemodialysis ◽  
Frequent Hemodialysis

When is more frequent hemodialysis beneficial?

2018 ◽  
Vol 31 (4) ◽  
pp. 332-342 ◽  
Author(s):  
Rita S. Suri ◽  
Alan S. Kliger
Keyword(s):  
More Frequent Hemodialysis ◽  
Frequent Hemodialysis

Is more frequent hemodialysis beneficial and what is the evidence?

2004 ◽  
Vol 13 (6) ◽  
pp. 631-635 ◽  
Author(s):  
Robert M Lindsay ◽  
Gihad Nesrallah ◽  
Rita Suri ◽  
Amit Garg ◽  
Louise Moist
Keyword(s):  
More Frequent Hemodialysis ◽  
Frequent Hemodialysis

Volume of urea cleared as a therapy dosing guide for more frequent hemodialysis

2018 ◽  
Vol 23 (1) ◽  
pp. 42-49 ◽  
Author(s):  
John K. Leypoldt ◽  
Eric D. Weinhandl ◽  
Allan J. Collins
Keyword(s):  
More Frequent Hemodialysis ◽  
Frequent Hemodialysis

scholarly journals Changes in Biomarker Profile and Left Ventricular Hypertrophy Regression: Results from the Frequent Hemodialysis Network Trials

2018 ◽  
Vol 47 (3) ◽  
pp. 208-217 ◽  
Author(s):  
Christopher T. Chan ◽  
George A. Kaysen ◽  
Gerald J. Beck ◽  
Minwei Li ◽  
Joan Lo ◽  
...  
Keyword(s):  
Left Ventricular Hypertrophy ◽  
Ventricular Hypertrophy ◽  
Left Ventricular ◽  
Tissue Inhibitors Of Metalloproteinase ◽  
Observational Cohort ◽  
Blood Pressures ◽  
Cardiovascular Biomarker ◽  
More Frequent Hemodialysis ◽  
Post Hoc ◽  
Frequent Hemodialysis

Background: Regression of left ventricular hypertrophy (LVH) is feasible with more frequent hemodialysis (HD). We aimed to ascertain pathways associated with regression of left ventricular mass (LVM) in patients enrolled in the Frequent HD Network (FHN) trials. Methods: This was a post hoc observational cohort study. We hypothesized LVH regression with frequent HD was associated with a different cardiovascular biomarker profile. Regressors were defined as patients who achieved a reduction of more than 10% in LVM at 12 months. Progressors were defined as patients who had a minimum of 10% increase in LVM at 12 months. Results: Among 332 randomized patients, 243 had biomarker data available. Of these, 121 patients did not progress or regress, 77 were regressors, and 45 were progressors. Mean LVM change differed between regressors and progressors by –65.6 (–74.0 to –57.2) g, p < 0.001. Regressors had a median (interquartile range) increase in dialysis frequency (from 3.0 [3.0–3.0] to 4.9 [3–5.7] per week, p = 0.001) and reductions in pre-dialysis systolic (from 149.0 [136.0–162.0] to 136.0 [123.0–152.0] mm Hg, p < 0.001) and diastolic (from 83.0 [71.0–91.0] to 76.0 [68.0–84.0] mm Hg, p < 0.001) blood pressures. Klotho levels increased in regressors versus progressors (76.9 [10.5–143.3] pg/mL, p = 0.024). Tissue inhibitors of metalloproteinase (TIMP)-2 levels fell in regressors compared to progressors (–7,853 [–14,653 to –1,052] pg/mL, p = 0.024). TIMP-1 and log (brain natriuretic ­peptide [BNP]) levels also tended to fall in regressors. Changes in LVM correlated inversely with changes in klotho (r = –0.24, p = 0.014). ­Conclusions: Markers of collagen turnover and changes in klotho levels are potential novel pathways associated with regression of LVH in the dialysis population, which will require further prospective validation.

Sign in / Sign up

Export Citation Format

Share Document